Researchers from Duke CIVIC Vaccine Center (DCVC) developed an mRNA-lipid nanoparticle vaccine incorporating hemagglutinin antigens from 20 different influenza subtypes.
The National Institute of Allergy and Infectious Diseases (NIAID) Collaborative Influenza Vaccine Innovation Centers (CIVICs) program is addressing critical gaps in the prevention and control of influenza
Even with seasonal vaccines, there are still an estimated 290,000 to 650,000 deaths globally due to influenza infections according to the World Health Organization (WHO).
Dr. Stacey Schultz-Cherry @ NPR The work of CIVICs researcher Dr. Stacey Schultz-Cherry, together with her team at St. Jude Children’s Research Hospital, was featured
The Pathway to a Universal Influenza Vaccine In 2018, the National Institute of Allergy and Infectious Diseases (NIAID) unveiled its strategic plan for developing a
The initiation of the Collaborative Influenza Vaccine Innovation Centers (CIVICs) program was announced by the National Institute of Allergy and Infectious Diseases (NIAID), part of